SJR 10

This bill urges the U.S. Congress to increase funding for research into the therapeutic uses of psychedelic compounds, such as psilocybin and MDMA, for treating mental health conditions, substance use disorders, and chronic pain. It also calls for streamlining the approval process for psychedelic research, establishing a process for compassionate medical use under the Right to Try Act, and potentially rescheduling these compounds to reflect their therapeutic value and low abuse potential. The bill recognizes growing federal and state interest in psychedelic therapies and seeks to support further research and legal protections.